Jeffrey Hafkin

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

Florian von Groote-Bidlingmaier, R. F. Patientia, Epifanio Sánchez et al. · The Lancet Respiratory Medicine · 2019 · 163 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Vlado Perkovic, Hernán Trimarchi, Vladimı́r Tesař et al. · New England Journal of Medicine · 2025 · 34 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana

Jeffrey Hafkin, Chawangwa Modongo, Craig Newcomb et al. · The International Journal of Tuberculosis and Lung Disease · 2013 · 33 citations

Public Health, Health Sciences, Infectious Disease Control +16

Incidence and risk factors for incomplete <scp>HBV DNA</scp> suppression in <scp>HIV</scp>/<scp>HBV</scp>‐co‐infected patients initiating tenofovir‐based therapy

Jeffrey Hafkin, Melissa Osborn, A. Russell Localio et al. · Journal of Viral Hepatitis · 2013 · 25 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

Suresh Mallikaarjun, Moti Chapagain, T. Sasaki et al. · Antimicrobial Agents and Chemotherapy · 2020 · 24 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17